PMCID	SENTENCE_NUMBER	SENTENCE	SENTENCE_INDICES	IGNORANCE_CLASSIFICATION
PMC4438576.nxml.gz	0	['Identification of targets for rational pharmacological therapy in childhood craniopharyngioma\n\nAbstract\n\nIntroduction\n\nPediatric adamantinomatous craniopharyngioma (ACP) is a histologically benign but clinically aggressive brain tumor that arises from the sellar/suprasellar region.']	(0, 282)	FALSE
PMC4438576.nxml.gz	1	['Despite a high survival rate with current surgical and radiation therapy (75â\x80\x9395Â\xa0% at 10Â\xa0years), ACP is associated with debilitating visual, endocrine, neurocognitive and psychological morbidity, resulting in excheptionally poor quality of life for survivors.']	(283, 545)	FALSE
PMC4438576.nxml.gz	2	['Identification of an effective pharmacological therapy could drastically decrease morbidity and improve long term outcomes for children with ACP.']	(546, 691)	FALSE
PMC4438576.nxml.gz	3	['Results\n\nUsing mRNA microarray gene expression analysis of 15 ACP patient samples, we have found several pharmaceutical targets that are significantly and consistently overexpressed in our panel of ACP relative to other pediatric brain tumors, pituitary tumors, normal pituitary and normal brain tissue.']	(693, 996)	FALSE
PMC4438576.nxml.gz	4	['Among the most highly expressed are several targets of the kinase inhibitor dasatinib â\x80\x93 LCK, EPHA2 and SRC; EGFR pathway targets â\x80\x93 AREG, EGFR and ERBB3; and other potentially actionable cancer targets â\x80\x93 SHH, MMP9 and MMP12.']	(997, 1226)	FALSE
PMC4438576.nxml.gz	5	['We confirm by western blot that a subset of these targets is highly expressed in ACP primary tumor samples.']	(1227, 1334)	FALSE
PMC4438576.nxml.gz	6	['Conclusions\n\nWe report here the first published transcriptome for ACP and the identification of targets for rational therapy.']	(1336, 1461)	FALSE
PMC4438576.nxml.gz	7	['Experimental drugs targeting each of these gene products are currently being tested clinically and pre-clinically for the treatment of other tumor types.']	(1462, 1615)	FALSE
PMC4438576.nxml.gz	8	['This study provides a rationale for further pre-clinical and clinical studies of novel pharmacological treatments for ACP.']	(1616, 1738)	FALSE
PMC4438576.nxml.gz	9	['Development of mouse and cell culture models for ACP will further enable the translation of these targets from the lab to the clinic, potentially ushering in a new era in the treatment of ACP.']	(1739, 1931)	FALSE
PMC4438576.nxml.gz	10	['Introduction\n\nAdamantinomatous craniopharyngioma (ACP) is the most common non-neural brain tumor with an incidence of approximately 1.9 cases/million patient-years in children.']	(1933, 2109)	FALSE
PMC4438576.nxml.gz	11	['Due to its sensitive sellar/suprasellar location and propensity to form large cysts, ACP often compresses and damages vital structures of the pituitary, hypothalamus and visual apparatus.']	(2110, 2297)	FALSE
PMC4438576.nxml.gz	12	['Although seemingly well-demarcated on neuroimaging studies, histology reveals finger-like protrusions extending into neighboring visual and hypothalamic structures, eliciting tissue damage and gliosis.']	(2298, 2499)	FALSE
PMC4438576.nxml.gz	13	['This propensity to invade adjacent structures, in addition to the difficult surgical location, often precludes total resection in order to avoid the significantly increased risk of visual and hypothalamic damage associated with attempts to completely remove the tumor.']	(2500, 2768)	FALSE
PMC4438576.nxml.gz	14	['The current standard of subtotal resection followed by radiation reduces some of the morbidity, however, it makes recurrence relatively common, even after apparently successful primary therapy.']	(2769, 2962)	FALSE
PMC4438576.nxml.gz	15	['Outcomes after recurrence are poorer, with significantly higher mortality and morbidity than after primary treatment.']	(2963, 3080)	FALSE
PMC4438576.nxml.gz	16	['While conservative surgery and radiation confer low mortality, the morbidity for survivors is still unacceptably high.']	(3082, 3200)	FALSE
PMC4438576.nxml.gz	17	['Variable morbidities are associated with ACP but include endocrine, neurological, vascular, psychological and visual deficits.']	(3201, 3327)	FALSE
PMC4438576.nxml.gz	18	['As a result, ACP has been associated with the lowest quality of life (QoL) scores of any pediatric brain tumor.']	(3328, 3439)	FALSE
PMC4438576.nxml.gz	19	['Lifelong care is necessary for most childhood craniopharyngioma patients and ACP and is considered by many to be a chronic disease.']	(3440, 3571)	FALSE
PMC4438576.nxml.gz	20	['The introduction of rational therapy to treat craniopharyngioma could drastically reduce the morbidity associated with both the primary disease and current treatments by reducing the extent of resection and/or reducing or eliminating the need for subsequent radiation.']	(3572, 3840)	FALSE
PMC4438576.nxml.gz	21	['Such a paradigm change in ACP treatment is critical to improving long term QoL for patients with this debilitating disease.']	(3841, 3964)	FALSE
PMC4438576.nxml.gz	22	['Progress regarding our understanding of the biological drivers of ACP growth has been slowed by the relative rarity of the tumor and the recalcitrance of ACP cells to laboratory growth.']	(3966, 4151)	FALSE
PMC4438576.nxml.gz	23	['Lack of knowledge of the underlying biology, combined with the clinical complexity of ACP have led to an absence of standard systemic antitumor therapies.']	(4152, 4306)	FALSE
PMC4438576.nxml.gz	24	['Few attempts to remedy this deficit have been made, in part because current therapy has acceptable survival outcomes.']	(4307, 4424)	FALSE
PMC4438576.nxml.gz	25	['Nevertheless, substantial progress has been made recently through tissue banking collaborations and â\x80\x9comicsâ\x80\x9d approaches.']	(4425, 4548)	FALSE
PMC4438576.nxml.gz	26	['Virtually all craniopharyngiomas in childhood are of the adamantinomatous type (ACP), contrasting with adults in whom up to 10Â\xa0% of craniopharyngiomas are papillary, and are now known to be driven by BRAF V600E mutations.']	(4550, 4772)	FALSE
PMC4438576.nxml.gz	27	['The only known genetic alterations in adamatinomatous craniopharyngioma (ACP) are point mutations in exon 3 of CTNNB1 that lead to Î²-catenin accumulation and upregulation of downstream target gene expression.']	(4773, 4982)	FALSE
PMC4438576.nxml.gz	28	['While the reported frequency of CTNNB1 sequence alterations ranges from 16â\x80\x93100Â\xa0%, Brastianos and colleagues recently used whole exome sequencing and mass spectrometric genotyping to identify CTNNB1 mutations in 92â\x80\x9396Â\xa0% of ACP.']	(4983, 5215)	FALSE
PMC4438576.nxml.gz	29	['It is likely, however, that genetic, epigenetic or other biological factors in addition to CTNNB1 mutation contribute to the pathogenesis of ACP.']	(5216, 5361)	FALSE
PMC4438576.nxml.gz	30	['For instance, Larkin and colleagues described 2 tumors that harbored alterations in both CTNNB1 and BRAF.']	(5362, 5467)	FALSE
PMC4438576.nxml.gz	31	['Furthermore, ACP tumors with CTNNB1 mutation contain cells that do not demonstrate intranuclear Î²-catenin accumulation and it has been suggested that some of the cells that comprise the tumor may not actually be CTNNB1 mutant â\x80\x9ctumorâ\x80\x9d cells at all.']	(5468, 5720)	FALSE
PMC4438576.nxml.gz	32	['EGFR pathway activation has also recently been identified as a driver of migration and growth using in-vitro and xenotransplant models of ACP, supporting the testing of EGFR targeted therapies.']	(5721, 5914)	FALSE
PMC4438576.nxml.gz	33	['In addition, through an embryonic mouse model of human ACP, the role of pituitary stem cells in ACP tumorigenesis is being explored.']	(5915, 6047)	FALSE
PMC4438576.nxml.gz	34	['The recent identification of BRAF mutations in papillary craniopharyngioma changes the paradigm in treating this (primarily adult) tumor because of the availability of BRAF V600E-specific inhibitors.']	(6049, 6248)	FALSE
PMC4438576.nxml.gz	35	['By contrast, the identification of Î²-catenin/Wnt signaling as a driver of adamantinomatous craniopharyngioma (ACP) is of little use in guiding therapy because inhibitors of Wnt signaling downstream of Î²-catenin/TCF/LEF are not yet clinically viable.']	(6249, 6500)	FALSE
PMC4438576.nxml.gz	36	['Global gene expression analysis is therefore critical for determining the epigenetic effect of aberrant Î²-catenin driven transcription in ACP in order to find targets for rational therapy.']	(6501, 6690)	FALSE
PMC4438576.nxml.gz	37	['Materials and methods\n\nTumor samples\n\nCaption (TABLE-WRAP): TABLE 1\n\nÎ²-catenin and BRAF mutational status of tumor and age of 15 ACP patient cohort used in transcriptome study\n\nUPN\tÎ²-Catenin\tBRAF\tAge at Dx\t \t411\tS33F\tWT\t2\t \t463\tS37F\tWT\t4\t \t598\tS37C\tWT\t18\t \t646\tD32N\tWT\t7\t \t673\tS37F\tWT\t2\t \t740\tS33F\tWT\t12\t \t802\tWT\tWT\t7\t \t883\tWT\tWT\t6\t \t956\tS37C\tWT\t9\t \t980\tD32N\tWT\t13\t \t1000\tS45F\tWT\t0\t \t9109\tWT\tWT\t9\t \t9201\tT41I\tWT\t-\t \t9202\tT41I\tWT\t-\t \t9302\tWT\tWT\t-\t \t\n\nA total of 15 ACP tumor samples were included in this study.']	(6692, 7204)	FALSE
PMC4438576.nxml.gz	38	['Eleven specimens were from patients who underwent surgical procedures at Childrenâ\x80\x99s Hospital Colorado, from 1995 through 2014.']	(7205, 7333)	FALSE
PMC4438576.nxml.gz	39	['Tumor samples were collected at the time of surgery and snap frozen in liquid nitrogen or fixed in formalin and paraffin embedded.']	(7334, 7464)	FALSE
PMC4438576.nxml.gz	40	['Additional specimens were contributed by the University of Alabama, Columbia University and Phoenix Childrenâ\x80\x99s Hospital.']	(7465, 7587)	FALSE
PMC4438576.nxml.gz	41	['The median age of this cohort was 7Â\xa0years (range 0 to 18Â\xa0years) (TableÂ\xa01).']	(7588, 7665)	FALSE
PMC4438576.nxml.gz	42	['Purity of ACP tumor samples was determined by histological analysis using hematoxylin and eosin staining in addition to immunostaining for Î²-catenin.']	(7666, 7816)	FALSE
PMC4438576.nxml.gz	43	['A further 176 samples of other primary tumors and a variety of normal cerebral tissues were used for comparative purposes.']	(7817, 7939)	FALSE
PMC4438576.nxml.gz	44	['This cohort included samples from the spectrum of pediatric and adult brain tumor types (20 atypical teratoid/rhabdoid tumor (AT/RT), 5 choroid plexus papilloma (CPP), 46 ependymoma (EPN), 12 glioblastoma (GBM), 22 medulloblastoma (MED), 9 meningioma (MEN), 15 pilocytic astrocytoma (PA), 13 primitive neuroepithelial tumor (PNET)) and other peripheral pediatric solid tumors (6 malignant peripheral nerve sheath tumors (MPNST), 8 rhabdomyosarcoma (RMS)).']	(7940, 8395)	FALSE
PMC4438576.nxml.gz	45	['Specimens were classified according to WHO international histological tumor classification.']	(8396, 8487)	FALSE
PMC4438576.nxml.gz	46	['Normal pediatric brain samples from a variety of anatomic sites were obtained during routine epilepsy surgery or autopsy at Childrenâ\x80\x99s Hospital Colorado.']	(8488, 8643)	FALSE
PMC4438576.nxml.gz	47	['All samples were obtained in compliance with internal review board regulations (COMIRB #95-500 and #09-0906).']	(8644, 8753)	FALSE
PMC4438576.nxml.gz	48	['Nucleic acid extraction, amplification and microarray preparation\n\nRNA from all surgical specimens was extracted, amplified, labeled and hybridized to Affymetrix HG-U113 plus 2 microarray chips (Affymetrix, Santa Clara, CA, USA) according to manufacturerâ\x80\x99s instructions and as described previously.']	(8755, 9055)	FALSE
PMC4438576.nxml.gz	49	['SNaPshot analysis for CTNNB1 and BRAF mutations was performed at the University of Colorado Pathology Core per manufacturerâ\x80\x99s instructions and as described previously.']	(9056, 9225)	FALSE
PMC4438576.nxml.gz	50	['Patient characteristics, including presence or absence of CTNNB1 mutations by SNaPshot analysis, are shown in TableÂ\xa01.']	(9226, 9345)	FALSE
PMC4438576.nxml.gz	51	['SNaPshot analysis was also used to examine BRAF mutational status (TableÂ\xa01), specifically BRAF V600E, which was recently identified in papillary craniopharyngioma.']	(9346, 9510)	FALSE
PMC4438576.nxml.gz	52	['This mutation was not found in any ACP sample tested.']	(9511, 9564)	FALSE
PMC4438576.nxml.gz	53	['Microarray data analysis\n\nData analysis was performed in R (http://www.r-project.org), using packages publicly available through Bioconductor (http://www.bioconductor.org).']	(9566, 9738)	FALSE
PMC4438576.nxml.gz	54	['As a first step, the scanned microarray data were background corrected and normalized using the gcRMA algorithm resulting in log 2 gene expression values.']	(9739, 9893)	FALSE
PMC4438576.nxml.gz	55	['Publically available microarray CEL file data were obtained for 9 normal pituitary and 14 pituitary adenoma samples from GEO (GSE26966); these samples were chosen because they were processed in the same manner as ours and through the same microarray core lab.']	(9894, 10153)	FALSE
PMC4438576.nxml.gz	56	['These were combined with the ACP, other tumor, and normal brain cohort as detailed above.']	(10154, 10243)	FALSE
PMC4438576.nxml.gz	57	['Multiple probesets for a gene were then collapsed to 1 entry per gene, based on the mean best-expressed probeset for that gene.']	(10244, 10371)	FALSE
PMC4438576.nxml.gz	58	['Hierarchical clustering was performed using the normalized gene expression data.']	(10372, 10452)	FALSE
PMC4438576.nxml.gz	59	['Distances based on Spearman correlations were calculated for input to an agglomerative algorithm with use of complete linkage, as implemented in the Bioconductor hclust function.']	(10453, 10631)	FALSE
PMC4438576.nxml.gz	60	['These microarray data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database and are publicly accessible through GEO Series accession number GSE68015 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68015).']	(10632, 10900)	FALSE
PMC4438576.nxml.gz	61	['Differential gene expression between ACP and multiple other tumor and normal tissue types was calculated using the Bioconductor limma function.']	(10902, 11045)	FALSE
PMC4438576.nxml.gz	62	['Data were filtered before input to eliminate genes not expressed in any samples or that showed only limited variance across samples.']	(11046, 11178)	FALSE
PMC4438576.nxml.gz	63	['The limma function performs pair-wise comparisons between a target group and each of the other user-defined groups in the dataset.']	(11179, 11309)	FALSE
PMC4438576.nxml.gz	64	['It uses an Empirical Bayes approach to calculate a moderated t-statistic and calculates a false discovery rate (FDR) that accounts for multiple testing both within and across groups.']	(11310, 11492)	FALSE
PMC4438576.nxml.gz	65	['The unique molecular signature of ACP was defined as genes that showed significant differential expression in all of the pair-wise comparisons (FDR â\x89¤0.1 and mean fold difference â\x89¥1.5) and for which the mean difference was in the same direction when compared with all of the other clusters (i.e., either all upregulated or all downregulated in all of the comparisons with respect to ACP).']	(11493, 11884)	FALSE
PMC4438576.nxml.gz	66	['In further analyses, individual tumor gene expression of select genes involved in putative ACP development/biology were extracted from the normalized dataset.']	(11886, 12044)	FALSE
PMC4438576.nxml.gz	67	['For these comparisons, normalized hybridization intensity values for a selected gene for individual ACP samples were presented as fold-difference relative to the average of all other tumor and normal samples.']	(12045, 12253)	FALSE
PMC4438576.nxml.gz	68	['Data analysis using hierarchical clustering, NIH Database for Annotation, Visualization, and Integrated Discovery (DAVID) bioinformatics tools has been previously described.']	(12255, 12428)	FALSE
PMC4438576.nxml.gz	69	['Functional analysis of genes was performed with DAVID using the Gene Ontology, Protein Analysis Through Evolutionary Relationships (PANTHER) Biological Process and KEGG databases.']	(12429, 12608)	FALSE
PMC4438576.nxml.gz	70	['ACP upregulated genes were compared to known targets of FDA approved and other oncology drugs that had reached clinical trial stage, as published in the literature and compiled in Ingenuityâ\x80\x99s KnowledgeBase (Ingenuity Systems, www.ingenuity.com).']	(12609, 12856)	FALSE
PMC4438576.nxml.gz	71	['Oncology drug target gene expression in individual ACP samples (nâ\x80\x89=â\x80\x8915) was compared to all other tumor and normal tissue combined and assigned percentile scores.']	(12857, 13023)	FALSE
PMC4438576.nxml.gz	72	['Drug target genes that were consistently highly expressed (>66th percentile) in all ACP samples were identified, and then ranked according to the highest average percentile expression.']	(13024, 13208)	FALSE
PMC4438576.nxml.gz	73	['Western blot validation of functional isoforms of putative drug targets\n\nProtein levels of a selection of putative drug target genes in ACP were examined by Western blot analysis to validate the results of microarray analysis.']	(13210, 13436)	FALSE
PMC4438576.nxml.gz	74	['Snap frozen tumor samples were homogenized in RIPA buffer (Sigma) supplemented with protease and phosphatase inhibitors (Roche).']	(13437, 13565)	FALSE
PMC4438576.nxml.gz	75	['This study utilized 6 ACP samples and 3 each of AT/RT, EPN, GBM, MED, PA and normal brain (obtained from autopsy material).']	(13566, 13689)	FALSE
PMC4438576.nxml.gz	76	['Proteins samples (30Â\xa0Î¼g) were resolved on a 26 well Criterion Gel (BioRad) and transferred to Immobilon PVDF membrane (Millipore).']	(13690, 13822)	FALSE
PMC4438576.nxml.gz	77	['Membranes were probed with antibodies to SHH (Millipore #06-1106; 1:1000), MMP9 (Cell Signaling #3852; 1:1000), MMP12 (R&D Systems #AF917; 1:1000) and Actin (Cell Signaling #12262; 1:10,000).']	(13823, 14014)	FALSE
PMC4438576.nxml.gz	78	['Results\n\nIdentification of potential drug targets and ACP signature genes\n\nCaption (TABLE-WRAP): TABLE 2\n\nTop 20 therapeutic target genes overexpressed in ACP compared to normal brain tissues and a variety of CNS and peripheral malignancies\n\nSymbol\tGene name\tAverage percentile\t# of ACP >66th %-ile\tTherapeutic agents\tFold\tp-Value\t \tMMP12\tmatrix metallopeptidase 12\t99.4\t15\tAZD1236\t820\t3.03E-49\t \tSHH\tsonic hedgehog homolog\t98.9\t15\tErismodegib, Vismodegib\t96.8\t1.48E-48\t \tIL2RB\tinterleukin 2 receptor, beta\t96.7\t15\tDenileukin diftitox\t12.4\t4.87E-23\t \tLCK\tlymphocyte-specific protein tyrosine kinase\t95.2\t15\tDasatinib, Pazopanib\t5.50\t8.24E-16\t \tEPHA2\tEPH receptor A2\t95.1\t15\tDasatinib, Regorafenib\t16.6\t6.8E-16\t \tAREG\tAmphiregulin\t93.9\t15\tCetuximab\t20.8\t4.82E-17\t \tPIK3CD\tphosphoinositide-3-kinase, catalytic, delta\t93.8\t15\tIdelalisib\t6.79\t3.55E-10\t \tIL6R\tinterleukin 6 receptor\t91.9\t15\tSiltuximab\t6.13\t7.06E-8\t \tMMP9\tmatrix metallopeptidase 9\t91.6\t15\tAZD1236\t41.0\t9.79E-14\t \tEPCAM\tepithelial cell adhesion molecule\t90.7\t15\tTucotuzumab celmoleukin\t87.4\t2.01E-11\t \tSRC\tv-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog\t89.9\t15\tBosutinib, Dasatinib\t2.47\t3.71e-7\t \tMUC1\tmucin 1\t89.3\t15\tHuHMFG1\t6.30\t1.27E-7\t \tERBB3\tv-erb-b2 erythroblastic leukemia viral oncogene homolog 3\t86.7\t15\tLapatinib\t22.8\t4.19E-08\t \tTNFSF11\ttumor necrosis factor (ligand) superfamily, member 11\t91.7\t14\tDenosumab\t5.17\t4.28E-8\t \tMAPK14\tmitogen-activated protein kinase 14\t91.3\t14\tRegorafenib\t2.65\t2.49E-8\t \tPTGS2\tprostaglandin-endoperoxide synthase 2\t85.6\t14\tLenalidomide\t10.5\t9.23E-7\t \tRRAS\trelated RAS viral (r-ras) oncogene homolog\t85.4\t14\tSorafenib\t3.61\t2.32E-5\t \tPSMB1\tproteasome (prosome, macropain) subunit, beta type, 1\t83.8\t14\tCarfilzomib\t1.45\t5.85E-5\t \tEGFR\tepidermal growth factor receptor\t83.4\t14\tCetuximab, Erlotinib, Gefitinib, Lapatinib, etc.']	(14016, 15850)	FALSE
PMC4438576.nxml.gz	79	['7.57\t5.99E-05\t \tCD52\tCD52 molecule\t86.3\t13\tAlemtuzumab\t8.85\t4.51E-12\t \t\n\nCaption (Fig): FIG 1\n\nGene expression of potential targets for therapeutic intervention in ACP.']	(15851, 16019)	FALSE
PMC4438576.nxml.gz	80	['Expression of the indicated genes in ACP relative to a broad range of pediatric and adult brain tumor types: atypical teratoid/rhabdoid tumor (AT/RT), choroid plexus papilloma (CPP), ependymoma (EPN), glioblastoma multiforme (GBM), medulloblastoma (MED), meningioma (MEN), pilocytic astrocytoma (PA), primitive neuroectodermal tumor (PNET); peripheral pediatric solid tumors: malignant peripheral nerve sheath tumors (MPNST), rhabdomyosarcoma (RMS); in addition to malignant (pituitary adenoma) and normal pituitary (PT and N_P respectively); and normal brain and choroid plexus (N_B and N_CP respectively).']	(16020, 16627)	FALSE
PMC4438576.nxml.gz	81	['Dasatinib targets, LCK (lymphocyte-specific protein tyrosine kinase), EPHA2 (ephrin type-A receptor 2) and SRC (SRC proto-oncogene, non-receptor tyrosine kinase) (a).']	(16628, 16794)	FALSE
PMC4438576.nxml.gz	82	['Sonic hedgehog homolog (b).']	(16795, 16822)	FALSE
PMC4438576.nxml.gz	83	['Matrix metalloproteases 9 & 12 (c).']	(16823, 16858)	FALSE
PMC4438576.nxml.gz	84	['EGF pathway genes (d).']	(16859, 16881)	FALSE
PMC4438576.nxml.gz	85	['Values are expressed as log2 gene expression.']	(16882, 16927)	FALSE
PMC4438576.nxml.gz	86	['Horizontal red bars represent the mean, and error bars represent standard error of the mean (SEM)\n\nCaption (Fig): FIG 2\n\nOverexpression of active protein isoforms for SHH, MMP9 and MMP12 in ACP relative to other common pediatric brain tumors and normal brain.']	(16928, 17187)	FALSE
PMC4438576.nxml.gz	87	['Western blot analysis was used to determine latent preforms and cleaved active isoforms of the indicated proteins.']	(17188, 17302)	FALSE
PMC4438576.nxml.gz	88	['(Abbr: AT/RT, atypical teratoid/rhabdoid tumor; EPN, ependymoma; GBM, glioblastoma; MED, medulloblastoma; PA, pilocytic astrocytoma; Norm, normal brain)\n\nThe Î²-catenin and BRAF mutational status of each tumor sample is presented in TableÂ\xa01.']	(17303, 17545)	FALSE
PMC4438576.nxml.gz	89	['To explore the clinical relevance of our human pediatric ACP transcriptomic data, we screened the ACP signature for upregulation of genes associated with potential oncological drug targets for the treatment of these tumors.']	(17546, 17769)	FALSE
PMC4438576.nxml.gz	90	['Genes with high expression in ACP samples (nâ\x80\x89=â\x80\x8915) versus all other normal and neoplastic tissue samples (nâ\x80\x89=â\x80\x89195) were compared to known targets of oncology drugs as published in the literature and compiled in IPA KnowledgeBase.']	(17770, 18007)	FALSE
PMC4438576.nxml.gz	91	['This approach identified 13 drug target transcripts that were consistently overexpressed greater than the 66th percentile in ACP (TableÂ\xa02).']	(18008, 18148)	FALSE
PMC4438576.nxml.gz	92	['Three of the 13 consistently elevated drug target genes, LCK (lymphocyte-specific protein tyrosine kinase) (5.5 fold change (FC) in ACP versus all other samples combined, pâ\x80\x89=â\x80\x898.2â\x80\x89Ã\x97â\x80\x8910â\x88\x9216), EPHA2 (ephrin type-A receptor 2) (FCâ\x80\x89=â\x80\x8916.6, pâ\x80\x89=â\x80\x896.8â\x80\x89Ã\x97â\x80\x8910â\x88\x9216) and SRC (SRC proto-oncogene, non-receptor tyrosine kinase) (FCâ\x80\x89=â\x80\x892.5, pâ\x80\x89=â\x80\x893.7â\x80\x89Ã\x97â\x80\x8910â\x88\x927), are targets of a single FDA-approved drug, dasatinib (Fig.Â\xa01a).']	(18149, 18592)	FALSE
PMC4438576.nxml.gz	93	['Other combinations of genes overexpressed by ACP that could be targeted by a single drug were identified.']	(18593, 18698)	FALSE
PMC4438576.nxml.gz	94	['SHH (sonic hedgehog homolog) was shown to be highly expressed (FCâ\x80\x89=â\x80\x8996.9, pâ\x80\x89=â\x80\x891.5â\x80\x89Ã\x97â\x80\x8910â\x88\x9248) by ACP in this study (Fig.Â\xa01b), which is consistent with a recently developed mouse model of ACP and is the focus of oncology drug development for a number of tumor types.']	(18699, 18977)	FALSE
PMC4438576.nxml.gz	95	['SHH is translated as an inactive precursor 45Â\xa0kDa protein that is cleaved to generate an active 19Â\xa0kDa isoform.']	(18978, 19091)	FALSE
PMC4438576.nxml.gz	96	['As a putative drug target in ACP, we measured the levels of precursor and active isoforms for SHH by Western blot analysis.']	(19092, 19215)	FALSE
PMC4438576.nxml.gz	97	['Isoform levels were compared to a panel of other pediatric brain tumor types and normal brain.']	(19216, 19310)	FALSE
PMC4438576.nxml.gz	98	['This revealed that although the inactive precursor is expressed broadly across all tumor types, the active isoform is present at high levels only in ACP (Fig.Â\xa02).']	(19311, 19474)	FALSE
PMC4438576.nxml.gz	99	['ACP was also found to overexpress MMP9 (FCâ\x80\x89=â\x80\x8941.0, pâ\x80\x89=â\x80\x899.8â\x80\x89Ã\x97â\x80\x8910â\x88\x9214) and, more strikingly, MMP12 (FCâ\x80\x89=â\x80\x89819.7, pâ\x80\x89=â\x80\x893.0â\x80\x89Ã\x97â\x80\x8910â\x88\x9249) (Fig.Â\xa01c), which are both inhibited by AZD1236, a drug originally tested as a treatment for chronic obstructive pulmonary disease, but more recently investigated as an antitumor agent.']	(19475, 19816)	FALSE
PMC4438576.nxml.gz	100	['Like SHH, MMP9 and 12 are translated as inactive precursor proteins (92 and 55Â\xa0kDa respectively) that are cleaved to generate active isoforms (84 and 43/22Â\xa0kDa, respectively).']	(19817, 19994)	FALSE
PMC4438576.nxml.gz	101	['MMP isoform levels were compared to a panel of other pediatric brain tumor types and normal brain.']	(19995, 20093)	FALSE
PMC4438576.nxml.gz	102	['The latent precursor of MMP9 was identified in all tumor types but not normal brain, whereas the active isoform was only observed in ACP (Fig.Â\xa02).']	(20094, 20241)	FALSE
PMC4438576.nxml.gz	103	['Both the active and inactive isoforms of MMP12 were restricted to ACP (Fig.Â\xa02).']	(20242, 20322)	FALSE
PMC4438576.nxml.gz	104	['ACP additionally overexpressed AREG (FCâ\x80\x89=â\x80\x8920.9, pâ\x80\x89=â\x80\x894.8â\x80\x89Ã\x97â\x80\x8910â\x88\x9217), EGFR (FCâ\x80\x89=â\x80\x897.6, pâ\x80\x89=â\x80\x896.0â\x80\x89Ã\x97â\x80\x8910â\x88\x925) and ERBB3 (FCâ\x80\x89=â\x80\x8922.8, pâ\x80\x89=â\x80\x894.2â\x80\x89Ã\x97â\x80\x8910â\x88\x928) (Fig.Â\xa01d).']	(20323, 20515)	FALSE
PMC4438576.nxml.gz	105	['Each of these is a target of the numerous EGFR/ERBB pathway inhibiting drugs (cetuximab, erlotinib, lapatinib).']	(20516, 20627)	FALSE
PMC4438576.nxml.gz	106	['Transcriptome microarray clustering analyses\n\nCaption (Fig): FIG 3\n\nTranscriptome cluster analysis reveals similarities between ACP, meningioma and rhabdomyosarcoma, with no relationship to adult pituitary or pituitary adenoma.']	(20629, 20856)	FALSE
PMC4438576.nxml.gz	107	['Unbiased hierarchical clustering analysis of a panel of craniopharyngioma tumor samples compared to other pediatric tumors, normal brain tissue, pituitary tissue and adult pituitary adenomas.']	(20857, 21048)	FALSE
PMC4438576.nxml.gz	108	['The top 30Â\xa0% most variant genes, were used to generate the clustering dendrogram above.']	(21049, 21137)	FALSE
PMC4438576.nxml.gz	109	['(AT/RT, atypical teratoid/rhabdoid tumor; CPP, choroid plexus papilloma; MPNST, malignant peripheral nerve sheath tumor; GBM, glioblastoma multiforme)\n\nUnbiased hierarchical clustering of ACP gene expression data with data from the panel of normal and neoplastic CNS samples and some non-CNS pediatric tumor types (as used above) afforded us further insights into the biology of ACP.']	(21138, 21521)	FALSE
PMC4438576.nxml.gz	110	['ACP samples did not group with the cluster containing both normal and neoplastic pituitary (Fig.Â\xa03).']	(21522, 21623)	FALSE
PMC4438576.nxml.gz	111	['Surprisingly, ACP formed a distinct cluster within a larger cluster containing MEN, MPNST and RMS, a histologically heterogeneous group of tumors derived from various tissue types.']	(21624, 21804)	FALSE
PMC4438576.nxml.gz	112	['While it is perhaps not unexpected that a non-neural tumor like ACP clusters within this group of non-neural tumors, the fact that this cluster lies within the larger neuro-epithelial tumor and normal brain cluster and not with the pituitary tissues is difficult to interpret.']	(21805, 22081)	FALSE
PMC4438576.nxml.gz	113	['This raises the possibility that ACP may have a completely different origin than has been hypothesized; it is more likely however that it has differentiated in such a way that it shares a convergent expression profile in common with these tumors not due to a common tissue of origin.']	(22082, 22365)	FALSE
PMC4438576.nxml.gz	114	['Further analysis of the gene expression signatures responsible for these groupings as well as comparisons with papillary craniopharyngioma and head and neck cancers may give insight into the nature of these groupings.']	(22366, 22583)	FALSE
PMC4438576.nxml.gz	115	['Gene expression signature recapitulates ACP histopathological characteristics\n\nCaption (TABLE-WRAP): TABLE 3\n\nEnriched ontology terms associated with ACP-exclusive genes.']	(22585, 22755)	FALSE
PMC4438576.nxml.gz	116	['Limma identified 384 genes that were exclusively expressed in ACP compared to a normal brain tissues and a variety of CNS and peripheral malignancies.']	(22756, 22906)	FALSE
PMC4438576.nxml.gz	117	['DAVID was used to identify 23 enriched ontologies (FDRâ\x80\x89<â\x80\x890.005) that are shown ranked according to fold enrichment.']	(22907, 23026)	FALSE
PMC4438576.nxml.gz	118	['Abbreviation: Ontology ID prefix GO, Gene ontology biological process; BP, panther biological process; HSA, KEGG pathway; FDR, Benjamini false discovery rate adjusted p-value\n\nOntology term\tID\tFold enrichment\tp-Value\tFDR\t \tBiomineral formation\tGO:31214\t13.38\t2.53E-07\t5.50E-05\t \tOdontogenesis of dentine-containing tooth\tGO:42475\t11.28\t5.50E-06\t8.69E-04\t \tEpidermis development\tGO:8544\t11.06\t3.10E-27\t2.70E-24\t \tEctoderm development\tGO:7398\t10.78\t2.62E-28\t4.55E-25\t \tEpidermal cell differentiation\tGO:9913\t9.17\t6.27E-08\t1.56E-05\t \tKeratinocyte differentiation\tGO:30216\t9.17\t2.74E-07\t5.29E-05\t \tOdontogenesis\tGO:42476\t9.17\t5.23E-06\t9.09E-04\t \tEpithelial cell differentiation\tGO:30855\t8.43\t5.25E-13\t3.04E-10\t \tSkeletal development\tBP:201\t5.81\t7.85E-07\t1.96E-05\t \tEpithelium development\tGO:60429\t5.57\t1.46E-10\t6.33E-08\t \tBone development\tGO:60348\t5.37\t1.42E-05\t0.00205\t \tOssification\tGO:1503\t5.26\t4.46E-05\t0.00515\t \tCell structure\tBP:286\t3.72\t2.38E-14\t2.98E-12\t \tCell adhesion-mediated signaling\tBP:120\t3.66\t4.34E-08\t1.36E-06\t \tCytokine-cytokine receptor interaction\tHSA:4060\t3.38\t5.13E-05\t0.00557\t \tSkeletal system development\tGO:1501\t3.28\t2.06E-05\t0.00274\t \tCell structure and motility\tBP:285\t2.85\t2.68E-13\t1.68E-11\t \tCell adhesion\tGO:7155\t2.83\t4.39E-08\t1.52E-05\t \tBiological adhesion\tGO:22610\t2.82\t4.48E-08\t1.30E-05\t \tCell communication\tBP:274\t2.46\t6.08E-10\t2.53E-08\t \tCell adhesion\tBP:124\t2.30\t1.57E-04\t0.00280\t \tRegulation of cell proliferation\tGO:42127\t2.24\t3.69E-05\t0.00457\t \tSignal transduction\tBP:102\t1.43\t1.21E-04\t0.00251\t \t\n\nCaption (Fig): FIG 4\n\nExpression of the indicated genes in pediatric ACP.']	(23027, 24633)	FALSE
PMC4438576.nxml.gz	119	['p63 gene expression in the indicated tumor and normal tissue types (a).']	(24634, 24705)	FALSE
PMC4438576.nxml.gz	120	['Wnt pathway (b) and Î²-catenin (TCF/LEF) target gene expression (c).']	(24706, 24774)	FALSE
PMC4438576.nxml.gz	121	['Genes at chromosome 4p5 locus (d).']	(24775, 24809)	FALSE
PMC4438576.nxml.gz	122	['Values are expressed as log2 (a) or as fold-difference of individual ACP samples relative to the average of all other tumor and normal samples (b-d)\n\n\nIn a series of pair-wise comparisons (limma) with normal brain from a range of anatomic sites (including pituitary) and other brain (AT/RT, CPP, EPN, GBM, PA, MED, MEN, PNET), pituitary (PT) and peripheral solid tumors of childhood (MPNST, RMS) we identified genes that were overexpressed by ACP in all comparisons (FDR pâ\x80\x89<â\x80\x890.05).']	(24810, 25295)	FALSE
PMC4438576.nxml.gz	123	['These 384 ACP signature genes were then examined for enrichment (FDRâ\x80\x89<â\x80\x890.005) of gene ontology terms curated by Gene Ontology (biological processes), Panther (biological processes) and KEGG (pathways) databases using DAVID.']	(25296, 25523)	FALSE
PMC4438576.nxml.gz	124	['The majority of ontologic terms were comprised of ectodermal development-related genes (odontogenic, epidermal, epithelial development) (TableÂ\xa03).']	(25524, 25671)	FALSE
PMC4438576.nxml.gz	125	['Morphologic characteristics of odontogenesis in ACP range from deposits of calcium, which are evident on an x-ray, to development of whole teeth.']	(25672, 25817)	FALSE
PMC4438576.nxml.gz	126	['Specific genes contributing to odontogenesis signature include DLX2, ODAM, AMBN, AMELX, ENAM, TP63, EDAR, SHH, FGF4.']	(25818, 25934)	FALSE
PMC4438576.nxml.gz	127	['Epidermal morphology is also a defining histological feature of ACP, which is presumed to develop from nests of epithelium derived from Rathkeâ\x80\x99s cleft, with further development of non-viable wet keratin â\x80\x9cghost cellsâ\x80\x9d that resemble polyhedral, anucleated corneocytes (final step of keratinocyte differentiation).']	(25935, 26252)	FALSE
PMC4438576.nxml.gz	128	['The ACP genes that were highly expressed within these epidermal ontologies include numerous keratins (KRT5, KRT13, KRT14, KRT15, KRT16, KRT31, KRT34, KRT85) and laminins (LAMA3, LAMC2).']	(26253, 26438)	FALSE
PMC4438576.nxml.gz	129	['TP63 expression is also extraordinarily high in ACP (Fig.Â\xa04a); as a regulator of odontogenic, epidermal and keratinocyte development, and in regulation of stemness, p63 may play a critical role in ACP development and morphogenesis.']	(26439, 26671)	FALSE
PMC4438576.nxml.gz	130	['We also found that a cluster of odontogenic, cytokine and EGF family proteins at Chromosome 4p5 was highly overexpressed (as much as 4,000 fold) in ACP (Fig.Â\xa04d).']	(26672, 26835)	FALSE
PMC4438576.nxml.gz	131	['The genetic relevance of the high levels of expression at this locus is unclear.']	(26836, 26916)	FALSE
PMC4438576.nxml.gz	132	['Wnt pathway genes are expressed homogeneously and not at abnormally high levels in ACP (Fig.Â\xa04b), with the exception of the transcription factor (TCF)/lymphoid enhancer-binding factor (LEF) targets LEF1 and WNT5A.']	(26918, 27132)	FALSE
PMC4438576.nxml.gz	133	['However, consistent with the hypothesis that aberrant Wnt signaling (via mutant Î²-catenin) is responsible for the pathogenesis of ACP, Î²-catenin/TCF/LEF target genes are overexpressed an average of 32 fold over the other samples (Fig.Â\xa04c).']	(27133, 27375)	FALSE
PMC4438576.nxml.gz	134	['Caption (Fig): FIG 5\n\nExpression of the indicated developmental and cancer-related genes in individual pediatric ACP samples.']	(27377, 27502)	FALSE
PMC4438576.nxml.gz	135	['Epidermal growth factor (EGF) family genes (a).']	(27503, 27550)	FALSE
PMC4438576.nxml.gz	136	['Genes involved in pituitary development (b).']	(27551, 27595)	FALSE
PMC4438576.nxml.gz	137	['Developmental genes from the Notch (c), Six transcription factor (d), Sonic hedgehog (Shh) (e), Bone morphogenetic protein (BMP) and Fibroblast growth factor (FGF) (f) families.']	(27596, 27773)	FALSE
PMC4438576.nxml.gz	138	['Values expressed are fold-difference of individual ACP samples relative to the average of all other tumor and normal samples\n\nThe epigenetic profile of ACP may also give some insight into the developmental origins of this disease.']	(27774, 28004)	FALSE
PMC4438576.nxml.gz	139	['Genes involved in pituitary development (Fig.Â\xa05a) are not highly expressed with the exception of PITX1 & 2 which are established TCF/LEF targets.']	(28005, 28151)	FALSE
PMC4438576.nxml.gz	140	['Critical developmental and survival pathway gene expression patterns reveal a potential role for EGFR, Six family transcription factors, Shh and FGFs in ACP pathogenesis (Fig.Â\xa05bâ\x80\x93f).']	(28152, 28337)	FALSE
PMC4438576.nxml.gz	141	['Discussion\n\nIdentification of potential therapeutic targets in our transcriptomic analysis confirmed findings of previous studies that had identified SHH and EGFR pathway activity in ACP and provide further evidence that therapies targeting these pathways could be used successfully in treating ACP.']	(28339, 28638)	FALSE
PMC4438576.nxml.gz	142	['Transcriptomic analysis of ACP generated in a mouse model demonstrated high levels of SHH gene expression, suggesting a mitogenic autocrine/paracrine loop.']	(28639, 28794)	FALSE
PMC4438576.nxml.gz	143	['A subsequent study identified upregulation of members of the SHH signaling pathway in human specimens.']	(28795, 28897)	FALSE
PMC4438576.nxml.gz	144	['In vitro and xenotransplant model studies have demonstrated that EGFR activation is responsible for driving growth and migration in ACP.']	(28898, 29034)	FALSE
PMC4438576.nxml.gz	145	['The proven clinical utility of EGFR inhibition in the treatment of cancer makes EGFR targeted drugs an attractive approach to ACP treatment.']	(29035, 29175)	FALSE
PMC4438576.nxml.gz	146	['Our identification of high levels of EGFR ligand AREG provide a potential mechanism for EGFR activation in ACP that warrants further exploration.']	(29176, 29321)	FALSE
PMC4438576.nxml.gz	147	['Furthermore, AREG has been implicated as a paracrine/juxtacrine regulator of cell survival in other cancers and epidermal cell types.']	(29322, 29455)	FALSE
PMC4438576.nxml.gz	148	['It has also recently been suggested that ACP may be paracrine in nature (i.e.']	(29456, 29533)	FALSE
PMC4438576.nxml.gz	149	['the CTNNB1 mutant cells may promote the proliferation of another cell type that actually populates the tumor).']	(29534, 29644)	FALSE
PMC4438576.nxml.gz	150	['This hypothesis could explain the extensive intratumoral heterogeneity in ACP and perhaps the difficulty we and others have found in obtaining â\x80\x9cpureâ\x80\x9d tumor samples to accurately identify CTNNB1 mutations.']	(29645, 29853)	FALSE
PMC4438576.nxml.gz	151	['We also identified a number of additional novel potential drug targets.']	(29855, 29926)	FALSE
PMC4438576.nxml.gz	152	['One group, including LCK, EPHA2 and SRC, is targeted by the kinase inhibitor dasatinib.']	(29927, 30014)	FALSE
PMC4438576.nxml.gz	153	['Hundreds of trials are now underway using dasatinib to treat a wide variety of cancers beyond the few for which it currently has FDA approval.']	(30015, 30157)	FALSE
PMC4438576.nxml.gz	154	['A second group of targets we identified are extracellular proteases, of which many were strongly represented in our analysis; two in particular, MMPs 9 and 12, are targeted by the drug AZD1236.']	(30158, 30351)	FALSE
PMC4438576.nxml.gz	155	['MMP12, which we found expressed at very high levels, is a proteolytic factor that may contribute to the significant invasive phenotype that is a hallmark of ACP.']	(30352, 30513)	FALSE
PMC4438576.nxml.gz	156	['Previous studies have attempted to correlate proteinase activity with biological course in ACP including a study that confirmed the presence of MMP9 by immunohistochemistry.']	(30514, 30687)	FALSE
PMC4438576.nxml.gz	157	['The results of this transcriptomic study of human pediatric ACP shed further light on the biology of this tumor, reflect the odontogenic and epithelial characteristics in the pathology of ACP and recapitulate the origins of ACP from oral ectoderm.']	(30689, 30936)	FALSE
PMC4438576.nxml.gz	158	['The origins of ACP have long been the subject of speculation due to the oddity of their morphology and location.']	(30937, 31049)	FALSE
PMC4438576.nxml.gz	159	['Many consider ACP to be a congenital midline developmental malformation, but the (albeit infrequent) occurrence of ACP in late adulthood and variable presentation are difficult to reconcile with this hypothesis.']	(31050, 31261)	FALSE
PMC4438576.nxml.gz	160	['The recognition that Î²-catenin dysregulation is responsible for ACP have led to two conflicting mouse models for the formation of ACP â\x80\x93 in mice an ACP-like tumor can develop from targeted CTNNB1 mutations in either pituitary oral ectoderm precursors in developing mice embryos or in pituitary stem cells in post-natal mice.']	(31262, 31588)	FALSE
PMC4438576.nxml.gz	161	['The data presented here are consistent with the theory that ACP is a congenital malformation that develops from the improper closure of the craniophyrangeal duct from the oral ectoderm-derived remnants of Rathkeâ\x80\x99s pouch (TableÂ\xa03).']	(31589, 31822)	FALSE
PMC4438576.nxml.gz	162	['However, these data are not completely inconsistent with the hypothesis that ACP arises from an anterior pituitary stem cell that transdifferentiates toward an oral epithelial phenotype.']	(31823, 32009)	FALSE
PMC4438576.nxml.gz	163	['Further analysis of more ACP samples, including adult ACP, in addition to transcriptomic studies of neuropathologically distinct cell subtypes present within ACP tumors will contribute to our understanding of how these tumors form and perhaps how to better treat them.']	(32010, 32278)	FALSE
PMC4438576.nxml.gz	164	['Conclusions\n\nCurrent standard therapy for ACP is surgery and radiation, both of which lead to high morbidity in this sensitive region of the brain, especially in children, in whom these morbidities become a lifelong and life-altering disease.']	(32280, 32522)	FALSE
PMC4438576.nxml.gz	165	['Intracystic delivery of therapeutic agents (interferon-alpha, bleomycin or Ytrrium90) has shown some efficacy in treating ACP, but this approach is limited by the requirement of a single cyst in the presenting tumor and requires stereotactic surgery to place a catheter and Ommaya reservoir for delivery.']	(32523, 32827)	FALSE
PMC4438576.nxml.gz	166	['Systemic therapy could more safely and more effectively treat children with ACP.']	(32828, 32908)	FALSE
PMC4438576.nxml.gz	167	['However, progress has been hindered by the absence of in vitro or in vivo models of this tumor that would enable the unbiased screening of drug libraries.']	(32909, 33063)	FALSE
PMC4438576.nxml.gz	168	['This study forms the basis for further studies with rational therapies for ACP.']	(33064, 33143)	FALSE
PMC4438576.nxml.gz	169	['The recent development of ACP xenotransplants in immune deficient mice will enable pre-clinical testing of these rationally selected targeted therapies, providing further rationale for small studies on efficacy in augmenting surgery and radiation or in treating recurrent ACP.']	(33144, 33420)	FALSE
PMC4438576.nxml.gz	170	['These efforts, combined with further collaborations between centers and consortiums will provide the foundation for a randomized clinical trial using targeted agents to treat ACP in the near future.']	(33421, 33619)	FALSE
PMC4438576.nxml.gz	171	['Competing interests\n\nThe authors declare that they have no competing interests.']	(33621, 33700)	FALSE
PMC4438576.nxml.gz	172	['Authorsâ\x80\x99 contributions\n\nJMG, AMD, BKK-D, LG, NF and TCH designed the study.']	(33702, 33779)	FALSE
PMC4438576.nxml.gz	173	['AMD, VMA, AMG, BKK-D, MH, and TCH collected and processed the tumor samples.']	(33780, 33856)	FALSE
PMC4438576.nxml.gz	174	['JMG, AMD, DKB, VMA, KKR, AMG conducted the experiments.']	(33857, 33912)	FALSE
PMC4438576.nxml.gz	175	['JMG, AMD, DKB and TCH performed the transcriptomic data analysis.']	(33913, 33978)	FALSE
PMC4438576.nxml.gz	176	['JMJ, RCEA and AR provided tumor samples.']	(33979, 34019)	FALSE
PMC4438576.nxml.gz	177	['JMG, AMD and TCH drafted the manuscript with editorial input from all authors.']	(34020, 34098)	FALSE
PMC4438576.nxml.gz	178	['All authors read and approved the final manuscript.']	(34099, 34150)	FALSE
